Such an assumption can be confirmed by results from the present study showing that patients with hypopituitarism being on appropriate replacement therapies (patients with compensated hypopituitarism) had higher MBL levels comparing to those on inadequate replacement therapies (patients with non-compensated hypopituitarism, Figure 4 and Table 6). The gene discussed is MBL2; the disease is hypopituitarism.